Overview
MediWound Q2 2025 revenue rises 43% sequentially, beating analysts' expectations
Net loss widens to $13.3 mln, driven by non-cash financial expenses
Co establishes strategic research collaborations with Essity and Convatec for EscharEx trials
Outlook
Company expects full operational capacity for NexoBrid by year-end 2025
Company received $3.6 mln from U.S. DoD for NexoBrid development
MediWound continues EscharEx Phase III trial enrollment with new partnerships
Result Drivers
NEXOBRID ADOPTION - U.S. adoption of NexoBrid continues to grow, with Vericel reporting 52% year-over-year revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $5.70 mln | $5.68 mln (6 Analysts) |
Q2 EPS | -$1.23 | ||
Q2 Net Income | -$13.30 mln | ||
Q2 Adjusted EBITDA | Miss | -$4.50 mln | -$4.25 mln (2 Analysts) |
Q2 Gross Profit | $1.30 mln | ||
Q2 Operating Income | -$5.70 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mediwound Ltd is $30.50, about 38.5% above its August 13 closing price of $18.75
Press Release: ID:nGNXb8gMFJ
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。